AstraZeneca and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) today announced a collaborative program to support academic research proposals using open innovation as a catalyst for drug discovery. The program will connect expert physicians and scientists with a wide range of high-quality, small molecule compounds and biologics developed by AstraZeneca.
